LabTurbo Biotech Corporation Automation for Gene Detection of Taipei at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

LabTurbo Biotech Corporation Automation for Gene Detection

3f-1, No.150, Section 4, Chen-Der Road,, 111 Taipei
Telephone +1 609 6191858, +1 609 6191858

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is co-exhibitor of
Kaigo Co., Ltd.

Hall map

MEDICA 2021 hall map (Hall 3): stand F36

Fairground map

MEDICA 2021 fairground map: Hall 3


Emily Chiang



Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

  • 03  Diagnostic tests
  • 03.05  Infectious immunology testing
  • 03.05.01  Bacteriology testing

Bacteriology testing

  • 03  Diagnostic tests
  • 03.05  Infectious immunology testing
  • 03.05.02  Microbiological diagnosis, virology, equipment and systems for

Microbiological diagnosis, virology, equipment and systems for

  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.01  DNA testing
  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)

Polymerase chain reaction (PCR)

Our products

Product category: Polymerase chain reaction (PCR)

LabTurbo AIO SP-qPCR

Fully automated DNA/RNA extraction + qPCR system
Fully automate molecular testing by integrating DNA/RNA extraction, liquid handling and multi-channel real-time PCR. Achieve high quality multiplex gene detection with high sensitivity, high throughput and fast turnaround time.
  • High-quality, high-sensitivity molecular testing: 100% detection rate of COVID-19 confirmed by QCMD blind test
  • Fast turnaround time: 6 detections in 1.5 hours, 48 detections in 2 hours, 48 detections/hour in continuous loading mode
  • Quick and easy system preparation: simply load the samples and plastic consumables in less than 10 minutes and the system is ready to use
  • Additional value: Up to 5 target multiplex qPCR for rapid multi-target detection with fewer PCR wells. Save reagents, increase throughput and boost overall profits
  • Break the barriers with full automation: Reduce time, decrease labor, and bypass the high demand for technical staff
  • Multiple applications on one system: run multiple detections and sample types on the same system, including UTI, RPP, STI, GI, infectious diseases, and many more

More Less

Product category: DNA testing

LabTurbo extraction system

Versatile system for sample transfer, liquid handling, DNA/RNA extraction and PCR setup
Full automation of the entire DNA/RNA extraction process with versatile liquid handling capabilities. Recovery of high quality nucleic acids with fast turnaround time, high throughput and excellent sensitivity
  • Automates all steps of sample preparation: Put samples into the system and get PCR-ready products. Avoid handling errors, deviations and a high demand for technical staff
  • High throughput and streamlined process: Achieve consistent results with fast turnaround time. Hundreds of sample preparations can be performed per day per system
  • Excellent sensitivity with membrane column method: Better removal of contaminants with scalable sample introduction of up to 2 ml for higher sensitivity. Easy processing of difficult sample types (blood, urine, stool, swabs, etc.)
  • User-friendly design and operation: bench set-up in less than 5 minutes with automatic reagent management and easy maintenance. Design to avoid cross contamination and UV light included in delivery

More Less

Company news



02 Feb 2021

LabTurbo Biotech receives national innovation award

On Dec. 1, LabTurbo was also awarded the Pharmaceutical Science and Technology Research and Development Award, presented by the Ministry of Health and Welfare and the Ministry of Economic Affairs. The award ceremony will be held on December 15.
Eric Dai (fifth from left), the CEO of LabTurbo Biotech, the research team led by Dr. Xu Huiling (fourth from left) of the Institute of Preventive Medicine, Cai Shihong (third from left), director of Tri-Service General Hospital, and his group of doctors pose with the National Innovation Award.

Eric Dai, CEO of LabTurbo Biotech, expressed special thanks to researchers at the National Defense Medical Center's Institute of Preventive Medicine for their outstanding work and support with LabTurbo devices. During the epidemic, researchers used the devices for blind clinical trials. In early March, the Institute of Preventive Medicine was approved by the Central Epidemic Command Center as a quarantine facility for the study of severe infectious pneumonia. In May, LabTurbo became the second manufacturer to receive Taiwan's TFDA Emergency Use Authorization (EUA) and Ministry of Health and Welfare approval to manufacture medical devices.
LabTurbo is an affiliated company of Taigen Bioscience Corporation. The results of numerous scientific journals show that the fully automated nuclear extraction and gene detection system (AIO 48) achieves high sensitivity in detecting coronaviruses, which is several times higher than the sensitivity of similar equipment from foreign companies. In addition, it has passed the sample blank tests of several first-class third-party vendors with an accuracy rate of 100%, while the selling price is only one-third to one-half of the products of the leading overseas vendors. As a result, the AIO 48 is widely used by medical institutions and hospitals, research institutes and government agencies.

As the only institute in Taiwan that has a biosafety laboratory with a high protection level of P4, the Institute of Preventive Medicine of the National Defense Medical Center was the first institute to use AIO 48 for epidemic prevention. Thanks to the clinical evidence provided by the Institute of Preventive Medicine and Tri-Service General Hospital, LabTurbo's products have been successfully used in many hospitals and facilities for pathogen screening to detect viruses and ultimately prevent epidemics.

Assuming the COVID 19 pandemic continues, there is still a great need for detection devices worldwide, Eric Dai said. Because the AIO 48 can process large volumes of samples simultaneously, requires fewer personnel, simplifies the detection process, and reduces the variation caused by manual sample handling, it is highly competitive because it enables rapid screening, requires little space, and is very easy to use. Currently, LabTurbo exports 80% of its AIO 48 systems abroad, particularly to the United States, the Philippines, Spain, Romania and the Czech Republic. In view of the market demand next year, LabTurbo will not only actively work to build the second supply chain, but also make tremendous efforts to increase brand awareness.

As a pioneer in epidemic prevention in Taiwan, LabTurbo participated in the medical technology fair "Taiwan Healthcare+ Expo" in the Precision Detection Section at Nangang Exhibition Hall for the first time yesterday (December 3, 2020) to show its products to the world and communicate with others. The expo will be held from December 3 to 6, 2020. Eric Dai revealed that AIO is a multi-gene testing device that can detect numerous pathogens simultaneously. LabTurbo has already entered into a positive collaboration with the Institute of Preventive Medicine to conduct clinical trials, with an effort to deploy the device early to address any epidemic prevention needs in the future.

More Less

25 Jan 2021

LabTurbo Biotech receives award from Taiwanese Ministry of Health and Welfare

The Ministry of Health and Welfare, in collaboration with the Ministry of Economic Affairs, held the 2020 Pharmaceutical Science and Technology Research Award Ceremony on December 15, 2020. There were a total of 55 competing products, breaking all previous records. It was a fierce competition. After months of review, the review team decided that 15 products stood out from the rest and were awarded Gold, Silver or Bronze. This was a record for the number of products awarded. This shows the innovation of the medical and biotechnology industry and its achievements.
Over the past decade, the biotechnology industry, which is one of the six core industries heavily supported by the Taiwanese government, has experienced rapid growth. Innovative drugs and medical instruments are expected to be the main driving force of Taiwan's biotechnology industry, which will gain a foothold in the global market in the future. At the award ceremony, all submitted products were divided into three categories: Pharmaceuticals, Medical Devices and Manufacturing Technology. The award aims to recognize innovative technologies that have made significant contributions to effective drug or medical care for patients, thereby enhancing the global competence of the biotechnology industry in Taiwan.

This year, there were only three products that were awarded gold. One of them was the Caduceus Microarray Chip Scanner from Caduceus Biotechnology Inc. It was the first Taiwan-made product for this field. The scanner can be used to test chromosomal abnormalities in fetal or neonatal development, allergens, drugs and crops. It can also be used to identify developing cancer markers. The second product was Co-Midis tablets developed by Standard Chem & Pharm Co. A combination drug of telmisartan and amlodipine, Co-Midis Tablets works through two complementary mechanisms, making it the latest drug to lower blood pressure in clinical use. The third product to be awarded Gold was the LeSONO LU700 handheld wireless ultrasound device developed by LELTEK INC. This is a miniaturized medical ultrasound system that provides physicians and researchers with high-resolution ultrasound images for analysis in various clinical settings.

The silver and bronze awards recognized six products each, including products related to COVID-19, such as a detection technology developed to find antibodies to the new coronavirus and a product that can be used to care for patients infected with the virus from a safe distance. LabTurbo Biotech Corporation received Silver for its AIO Full-Process Automatic Nucleic Acid Extraction and Gene Testing System, which has been shown to improve detection testing efficiency. A bronze award went to Excelsior Bio-Systems Incorporation for their Rapid Test Reagent for Antibodies to COVID-19, a product that has already been approved by the Department of Health and Welfare. A bronze award also went to Somnics Inc. for its platform for secure remote physical analysis to solve the problem of caring for patients quarantined at home during epidemic prevention. All of the winning products demonstrate the ability of Taiwan's scientific and research teams to connect with the world's cutting-edge technology to play a key role in epidemic prevention.
The industry index was created with the help of the Research and Development Award for Pharmaceutical Science and Technology. All companies awarded so far have performed well in their respective fields. Next year will be the 20th anniversary of the Pharmaceutical Science and Technology Research and Development Award. It is expected that even more outstanding pharmaceutical, medical device and manufacturing technology companies will participate in the competition with their innovative products. In addition, all circles, including industry, governments, universities and research institutes, are encouraged to make joint efforts to create brand value in the biotechnology industry in Taiwan and enhance international expertise in this field.

More Less

14 Nov 2020

LabTurbo Biotech, a biotech company focused on the development of

LabTurbo Biotech, a biotech company specializing in the development, manufacturing and marketing of nucleic acid extraction reagents, fully automated molecular diagnostic instruments and reagents, and automated instrument customization services.

The LabTurbo team is accomplished and knowledgeable in molecular diagnostics and scientific research. In addition to customer service, we also learn a lot about consumer needs and what researchers want. We have also supported LabTurbo Biotech's core research and development, where we have gained a solid foundation and skills for our work. Our strong background ensures that we have not only basic customer service, but also a lot of specific and in-depth information to help clients solve various problems they know or have not yet found.

We create an effective on-site assessment of consumer needs in line with our working patterns and customer interaction experience, ensuring that the company's offerings are updated to meet evolving customer expectations.

We ensure that improvements needed by customers are addressed in a timely manner. We have the ability and inert versatility to change plans and ensure that the services offered to consumers exceed their expectations. We are able to meet the needs of clients through our excellent listening, decision making and expertise
customer service capabilities.

As a customer service specialist, we demonstrate a high level of loyalty and dedication to our jobs. This spurred us to successfully complete our business trip to the United States for a highly complex research and molecular diagnostics laboratory installing the LabTurbo 48 Compact System. To maintain a good customer relationship, we provide prompt support when customers have requests and questions. Our willingness to assist in an on-site review of increasing customer needs with exceptional consistency and decision-making ability to maintain optimal customer satisfaction. This would further ensure that evolving consumer expectations are met in deciding to resolve the issue by liaising with the appropriate business offices, contributing to improved consumer service.

More Less

About us

Company portrait

LabTurbo emerged from the automatic nucleic acid division established by "Taigen Bioscience Co., Ltd." in 2000, and has been focusing on automatic nucleic acid technology development, product manufacturing and sales for the past 20 years. LabTurbo has successively obtained over 10 patents in Taiwan, the United States, China, Japan, South Korea, Germany and many other countries, and has been preparing for the global gene detection market. Due to the significant progress of the global gene detection and molecular diagnostics market, LabTurbo Biotech Corporation was officially established in June 2019 to research, manufacture and provide fast, accurate, automated and high-throughput gene detection systems and kits. LabTurbo has invested the funds in the development of fully automated high throughput genetic testing systems and diversified the applications of LabTurbo AIO SP-qPCR system for global market expansion.

Company data

Sales volume 50-99 Mio US $
Export content max. 25%
Number of employees 50-99
Foundation 1992
Area of business Diagnostic tests